- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04219826
Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM (REDWOOD-HCM)
January 8, 2024 updated by: Cytokinetics
A Multi-Center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy
This study is being performed to understand the effect of different doses of CK-3773274 on patients with hypertrophic cardiomyopathy (HCM).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
96
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Firenze, Italy
- Azienda Ospedaliero Universitaria Careggi
-
-
-
-
-
Rotterdam, Netherlands
- Erasmus University Medical Center (Erasmus MC)
-
-
-
-
-
A Coruña, Spain, 15003
- Complejo Hospitalario Universitario A Coruña
-
Madrid, Spain
- Hospital Universitario Puerta de Hierro de Majadahonda
-
-
-
-
California
-
Los Angeles, California, United States, 90048
- Cedar-Sinai Medical Center
-
San Francisco, California, United States, 94143
- UCSF Medical Center
-
-
Illinois
-
Evanston, Illinois, United States, 60208
- Northwestern University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Michigan Medicine - University of Michigan
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
New York
-
New York, New York, United States, 10016
- New York University Langone Health Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28203
- Carolinas Medical Center
-
Durham, North Carolina, United States, 27713
- Duke Cardiology at Southpoint
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania (University of Pennsylvania School of Medicine)
-
Pittsburgh, Pennsylvania, United States, 15213
- UMPC Heart and Vascular Institute
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern Medical Center
-
Houston, Texas, United States, 77030
- Houston Methodist Hospital
-
-
Utah
-
Murray, Utah, United States, 84107
- Intermountain Medical Center
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia Health System
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria
- Males and females between 18 and 85 years of age at screening.
- Body weight is ≥45 kg at screening.
Diagnosed with HCM per the following criteria:
- Has left ventricular (LV) hypertrophy with non-dilated LV chamber in the absence of other cardiac disease.
- Has minimal wall thickness ≥15 mm (minimal wall thickness ≥13 mm is acceptable with a positive family history of HCM or with a known disease-causing gene mutation).
- Adequate acoustic windows for echocardiography.
For Cohorts 1, 2 and 3 has LVOT-G during screening as follows:
- Resting gradient ≥50 mmHg OR
- Resting gradient ≥30 mmHg and <50 mmHg with post-Valsalva LVOT-G ≥50 mmHg
- For Cohort 4 has resting and post-Valsalva LVOT-G < 30 mmHg at the time of screening
- For Cohort 4 has elevated NT-proBNP > 300 pg/mL at the time of screening
- LVEF ≥60% at screening.
- New York Heart Association (NYHA) Class II or III at screening.
- Patients on beta-blockers, verapamil, diltiazem, or ranolazine should have been on stable doses for >4 weeks prior to randomization and anticipate remaining on the same medication regimen during the study.
- For Cohort 3: Patients must be taking disopyramide. Patients should have been on stable disopyramide doses for >4 weeks prior to screening and anticipate remaining on the same medication regimen during the study.
Exclusion Criteria
- Aortic stenosis or fixed subaortic obstruction.
- Known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM (eg, Noonan syndrome, Fabry disease, amyloidosis).
- History of LV systolic dysfunction (LVEF <45%) at any time during their clinical course.
- Documented history of current obstructive coronary artery disease (>70% stenosis in one or more epicardial coronary arteries) or documented history of myocardial infarction.
- Has been treated with septal reduction therapy (surgical myectomy or percutaneous alcohol septal ablation) or has plans for either treatment during the study period (Cohorts 1, 2, and 3 only). Patients having undergone septal reduction therapy > 12 months prior to screening who remain symptomatic from nHCM, and who meet all other criteria for inclusion, may be enrolled in Cohort 4.
- For Cohorts 1, 2 and 4: Has been treated with disopyramide or antiarrhythmic drugs that have negative inotropic activity within 4 weeks prior to screening. (For Cohort 3, use of disopyramide is required).
- Has any ECG abnormality considered by the investigator to pose a risk to patient safety (eg, second degree atrioventricular block type II).
- Paroxysmal atrial fibrillation or flutter documented during the screening period.
- Paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) ≤6 months prior to screening. (This exclusion does not apply if atrial fibrillation has been treated with anticoagulation and adequately rate-controlled for >6 months).
- History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to screening.
- Has received prior treatment with CK-3773274 or mavacamten.
- For Cohort 4: has any documented history of LVOT-G ≥ 30 mmHg at rest, with Valsalva, or with exercise (for subjects who have had prior septal reduction therapy, this exclusion criteria only applies to gradients detected following septal reduction therapy).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CK-3773274 - Cohort 1 (Obstructive HCM)
Subjects will receive doses of 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
|
CK-3773274 tablets administered orally
|
Placebo Comparator: Placebo - Cohort 1 (Obstructive HCM)
Subjects will receive placebo for up to 10 weeks
|
Placebo administered orally
|
Experimental: CK-3773274 - Cohort 2 (Obstructive HCM)
Subjects will receive doses 10 - 30 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
|
CK-3773274 tablets administered orally
|
Placebo Comparator: Placebo - Cohort 2 (Obstructive HCM)
Subjects will receive placebo for up to 10 weeks
|
Placebo administered orally
|
Experimental: CK-3773274 & disopyramide - Cohort 3 (Obstructive HCM)
Subjects will receive doses 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks while taking disopyramide
|
CK-3773274 tablets administered orally
|
Experimental: CK-3773274 - Cohort 4 (non-obstructive HCM)
Subjects will receive doses of 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
|
CK-3773274 tablets administered orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events observed during dosing of CK--3773274 in patients with HCM
Time Frame: 14 weeks
|
Patient incidence of reported adverse events (AEs)
|
14 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of left ventricular ejection fraction (LVEF) < 50% observed during dosing of CK-3773274 in patients with HCM
Time Frame: 14 weeks
|
Patient incidence of left ventricular ejection fraction (LVEF) < 50%
|
14 weeks
|
Incidence of serious adverse events observed during dosing of CK-3773274 in patients with HCM
Time Frame: 14 weeks
|
Patient incidence of reported serious adverse events (SAEs)
|
14 weeks
|
Concentration-response relationship of CK-3773274 on the resting left ventricular outflow tract gradient (LVOT-G) on echocardiogram over 10 weeks of treatment in patients with oHCM (Cohorts 1, 2, 3 only)
Time Frame: 10 weeks
|
Slope of the relationship of the plasma concentration of CK-3773274 to the change from baseline in the resting LVOT-G
|
10 weeks
|
Concentration-response relationship of CK-3773274 on the post-Valsalva left ventricular outflow tract gradient (LVOT-G) on echocardiogram over 10 weeks of treatment in patients with oHCM (Cohorts 1, 2, 3 only)
Time Frame: 10 weeks
|
Slope of the relationship of the plasma concentration of CK-3773274 to the change from baseline in the post-Valsalva LVOT-G
|
10 weeks
|
Dose response relationship on LVOT-G of CK-3773274 in patients with oHCM at rest (Cohorts 1, 2, 3 only)
Time Frame: 10 weeks
|
Change from baseline in resting LVOT-G over time as a function of dose
|
10 weeks
|
Dose response relationship on LVOT-G of CK-3773274 in patients with oHCM post-Valsalva (Cohorts 1, 2, 3 only)
Time Frame: 10 weeks
|
Change from baseline in post-Valsalva LVOT-G over time as a function of dose
|
10 weeks
|
Concentration-response relationship of CK-3773274 on left ventricular ejection fraction (LVEF) over 10 weeks of treatment in patients with HCM
Time Frame: Day 1 to End of Study (EOS) (Week 14)
|
Change from baseline in the resting LVEF
|
Day 1 to End of Study (EOS) (Week 14)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Cytokinetics, MD, Cytokinetics
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 10, 2020
Primary Completion (Actual)
February 28, 2023
Study Completion (Actual)
February 28, 2023
Study Registration Dates
First Submitted
January 3, 2020
First Submitted That Met QC Criteria
January 3, 2020
First Posted (Actual)
January 7, 2020
Study Record Updates
Last Update Posted (Actual)
January 10, 2024
Last Update Submitted That Met QC Criteria
January 8, 2024
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CY 6021
- 2019-002785-12 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertrophic Cardiomyopathy (HCM)
-
Bristol-Myers SquibbActive, not recruitingHypertrophic Cardiomyopathy (HCM)United States
-
CytokineticsEnrolling by invitationSymptomatic Hypertrophic Cardiomyopathy (HCM)United States, France, Israel, Spain, United Kingdom, Italy, Poland, Hungary, Denmark, Netherlands, Germany, Czechia, Portugal
-
Guangdong Provincial People's HospitalRecruitingHCM - Hypertrophic CardiomyopathyChina
-
IRCCS San RaffaeleMenarini International Operations Luxembourg SACompletedHCM - Hypertrophic Non-Obstructive CardiomyopathyItaly
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHypertrophic Cardiomyopathy (HCM)United States
-
Thibaud DamyCompletedCardiac Amyloidosis | Hypertrophic Cardiomyopathy (HCM) | Amyloidosis in Transthyretin (TTR)France
-
University Hospital HeidelbergCharite University, Berlin, Germany; Goethe University; University Medicine Greifswald and other collaboratorsRecruitingAmyloidosis | HCM - Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Inflammatory Cardiomyopathy | DCM - Dilated Cardiomyopathy | Non-ischemic Cardiomyopathy | HOCM - Hypertrophic Obstructive Cardiomyopathy | Left Ventricular Noncompaction CardiomyopathyGermany
-
French Cardiology SocietyCompleted1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy | 2- Obstructive Hypertrophic Cardiomyopathy | 3- Non Obstructive Hypertrophic CardiomyopathyFrance
-
University of Sao PauloCompletedNon-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyBrazil
-
Montreal Heart InstituteCanadian Institutes of Health Research (CIHR)Enrolling by invitationCardiomyopathies | Hypertrophic Cardiomyopathy | Hypertrophic Obstructive Cardiomyopathy | Familial Hypertrophic CardiomyopathyCanada
Clinical Trials on CK-3773274 (5 - 15 mg)
-
CytokineticsJi Xing Pharmaceuticals (Shanghai) Co., Ltd.CompletedObstructive Hypertrophic Cardiomyopathy (oHCM)United States, France, Spain, Portugal, Germany, China, United Kingdom, Israel, Netherlands, Denmark, Czechia, Hungary, Italy, Poland
-
CytokineticsEnrolling by invitationSymptomatic Hypertrophic Cardiomyopathy (HCM)United States, France, Israel, Spain, United Kingdom, Italy, Poland, Hungary, Denmark, Netherlands, Germany, Czechia, Portugal
-
CytokineticsCompletedHealthy Subjects | Symptomatic Obstructive Hypertrophic CardiomyopathyUnited States
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.RecruitingObstructive Hypertrophic CardiomyopathyChina
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.CytokineticsCompletedHealthy Adult Subjects | Obstructive Hypertrophic CardiomyopathyChina
-
EstetraCompletedMenopause | ContraceptionBulgaria
-
CytokineticsCompletedAmyotrophic Lateral SclerosisUnited States
-
CytokineticsCompletedIntermittent Claudication | Peripheral Artery DiseaseUnited States
-
CytokineticsRecruitingObstructive Hypertrophic Cardiomyopathy (oHCM)United States, Denmark, Spain, Netherlands, United Kingdom, France, China, Israel, Germany, Italy, Hungary, Canada
-
CytokineticsNational Institute of Neurological Disorders and Stroke (NINDS)TerminatedMyasthenia GravisUnited States